MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 0.5% - Still a Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) was up 0.5% on Tuesday . The company traded as high as $1.89 and last traded at $1.84. Approximately 126,674 shares traded hands during trading, a decline of 45% from the average daily volume of 229,457 shares. The stock had previously closed at $1.83.

MAIA Biotechnology Stock Up 0.5%

The business's 50 day moving average is $1.84 and its two-hundred day moving average is $1.91. The firm has a market capitalization of $55.77 million, a P/E ratio of -2.33 and a beta of 0.03.

Insider Buying and Selling

In related news, Director Stan Smith purchased 33,333 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average price of $1.50 per share, with a total value of $49,999.50. Following the purchase, the director owned 1,305,059 shares of the company's stock, valued at $1,957,588.50. This trade represents a 2.62% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 32.32% of the company's stock.

Institutional Investors Weigh In On MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 39,057 shares of the company's stock, valued at approximately $77,000. Jane Street Group LLC owned 0.15% of MAIA Biotechnology as of its most recent SEC filing. Institutional investors own 5.65% of the company's stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.